ClinicalTrials.gg
Status unknownNCT03252067Updated Aug 17, 2017

Tear Concentrations and Pharmacokinetics of Azithromycin Eye Drops in Healthy Volunteers

A Phase 1 interventional study of azithromycin eyedrop in Pharmacokinetics, sponsored by Beijing Tongren Hospital. Status unknown at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-08-17.

Sponsored by Beijing Tongren Hospital · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Aug 2017), so the status shown — last known as Recruiting — may be out of date.
Phase
Phase 1
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

To evaluate azithromycin tear concentrations after one drop of azithromycin eyedrops (2.5ml/25mg) in healthy volunteers.

Read the detailed description

In this randomized, open, single-center study, 42 healthy volunteers will receive one drop of azithromycin into each eye. Azithromycin tear concentrations will be measured by LC-MS/MS at seven time points for 24 hours. Tolerability is evaluated.

02

Conditions studied

  • Pharmacokinetics

Browse trials for

Keywords

  • Azithromycin eyedrops, pharmacokinetics, tears
03

In context

Lacerations

174 studies on the registry are indexed under Lacerations; 43 are open to participants now.

This study's planned enrollment of 42 is below the median of 65 across 128 interventional studies indexed under Lacerations.

Browse Lacerations studies →

Lead sponsor

Beijing Tongren Hospital is the lead sponsor of 164 studies on the registry; 54 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 to 45 years old, male or female;
  • in the range of 19 to 24;
  • eyes corrected visual acuity should be ≥ 1.0, intraocular pressure, slit lamp and fundus examination were normal, tear secretion function is normal;
  • Good compliance and voluntarily signed consent.

Exclusion criteria

Exclusion Criteria:

  • Have eye disease or systemic disease;
  • physical examination, laboratory tests, and chest X-ray examination abnormalities and has clinical significance;
  • , anti-, anti- and TPPA positive;
  • those who used eye drops two weeks before the test and who used any dosage form of azithromycin;
  • known to azithromycin or macrolide-related varieties of allergies or serious adverse reactions;
  • need to wear contact lenses during the test;
  • history of internal surgery or laser surgery history;
  • participated in other drug clinical trials in the past three months;
  • pregnant women and lactating women, or in the growth period without taking effective measures, menstrual period women;
  • mental illness or alcohol, history of drug abuse or inability to collaborate;
  • Any other circumstances that the investigators consider are unfit to participate in this study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
42 participants (estimated)

Study arms

  • Experimental
    azithromycin eyedrop

    Each of the subjects' eyes will receive single dose of azithromycin eyedrops and then attribute the time for tear sampling at seven time points up to 24 hours.

    Drug: azithromycin eyedrop

Interventions

  • Drugazithromycin eyedrop

    Tear samples will be collected using the strips.

06

What researchers measure

Primary outcomes

  1. the maximum concentration (Cmax)

    The tear samples are taken at 7 time points after administration up to 24 hours.The Cmax is calculated at the average concentration of each point.

    Time frame: The tear samples are taken at 7 time points after administration,including 10 minutes,half hour,2 hours,4 hours,8 hours,12 hours and 24hours.

  2. area under the curve (AUC)

    The tear samples are taken at 7 time points after administration up to 24 hours.The AUC is calculated at the average concentration of each point.

    Time frame: The tear samples are taken at 7 time points after administration,including 10 minutes,half hour,2 hours,4 hours,8 hours,12 hours and 24hours.

Secondary outcomes

  1. AEs

    Ocular and systemic adverse events

    Time frame: 24 hours

07

Study locations

1 of 1 sites recruiting
  • Beijing Tongren Hospital
    Beijing, Beijing 100730, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2017 (actual). Primary completion is estimated for Oct 2017, 2 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 4, 2017
First posted
Aug 17, 2017
StartActual
Aug 2, 2017
Primary completionEst.
Oct 31, 2017
CompletionEst.
Dec 31, 2017
Last update
Aug 17, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 17, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03252067
Collaborators
Grand Pharmaceutical (China) Co., Ltd.
Responsible party
Xiuli Zhao (Prof., Beijing Tongren Hospital) — Principal investigator
First posted
Aug 17, 2017
Start date
Aug 2, 2017
Primary completion
Oct 31, 2017 (estimated)
Completion
Dec 31, 2017 (estimated)
Last update
Aug 17, 2017

Study contacts

Feng Wu, Master
Contact
trdrug@126.com
010-58268486

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion